Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists - 1 Jan 2023

Haag Jennifer G, Wolsky Rebecca J, Moroney Marisa R, Sheren Jamie, Sheeder Jeanelle, Bitler Benjamin G, Corr Bradley R

Abstract excerpt

CTNNB1 mutations convey increased risk of recurrence in low-risk endometrial endometrioid carcinoma (EEC). Results from previous high-intermediate risk (HIR) cohorts are mixed. The aims of this study were to correlate CTNNB1 mutational status with clinical outcomes and to evaluate the relationship between CTNNB1 mutations and the 4 prognostic subgroups defined by The Cancer Genome Atlas in HIR EEC. CTNNB1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Endometrioid

Share to Endometrial Neoplasms

Share to Mutation

Share to Neoplasm Grading

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35283443
DOI: 10.1097/PGP.0000000000000865
PMCID: PMC9470776

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.PMID 35283443Read ↗

Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.Semantic proximity Read ↗

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.Semantic proximity Read ↗

Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid CarcinomaSemantic proximity Read ↗

Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.Semantic proximity Read ↗

Toward Biology-Driven Surveillance After Endometrial Cancer Treatment: A Molecular–Clinical Framework Integrating Recurrence PhenotypeSemantic proximity Read ↗

Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.Semantic proximity Read ↗

Impact of molecular classification on recurrence risk in endometrial cancer patients with lymph node metastasis: multicenter retrospective study.Semantic proximity Read ↗

Molecular testing for endometrial cancer: An SGO clinical practice statement.Semantic proximity Read ↗

Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low- and high-stage tumours.Semantic proximity Read ↗

Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.Semantic proximity Read ↗

Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.